Triad Investment Management Acquires New Stake in Amgen Inc. $AMGN

Triad Investment Management bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,503 shares of the medical research company’s stock, valued at approximately $542,000.

Other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its stake in Amgen by 2.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,073,540 shares of the medical research company’s stock valued at $377,725,000 after purchasing an additional 24,577 shares in the last quarter. Oslo Pensjonsforsikring AS bought a new stake in shares of Amgen in the 1st quarter worth $570,000. HORAN Wealth LLC lifted its holdings in shares of Amgen by 0.8% in the first quarter. HORAN Wealth LLC now owns 15,194 shares of the medical research company’s stock valued at $5,305,000 after buying an additional 119 shares during the period. DUTCH ASSET Corp acquired a new stake in shares of Amgen in the first quarter valued at $743,000. Finally, Madison Asset Management LLC boosted its stake in Amgen by 17.9% during the first quarter. Madison Asset Management LLC now owns 11,552 shares of the medical research company’s stock valued at $4,065,000 after buying an additional 1,755 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Up 0.6%

Shares of Amgen stock opened at $366.24 on Wednesday. The stock’s fifty day moving average is $348.98 and its 200-day moving average is $351.05. The firm has a market capitalization of $197.66 billion, a PE ratio of 25.49, a price-to-earnings-growth ratio of 3.68 and a beta of 0.41. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the company posted $4.90 EPS. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current year.

Analysts Set New Price Targets

AMGN has been the topic of a number of research analyst reports. Canaccord Genuity Group began coverage on Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 target price on the stock. UBS Group raised their price objective on shares of Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Weiss Ratings cut shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 15th. Truist Financial boosted their target price on shares of Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a report on Tuesday, July 7th. Finally, Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $356.62.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.